Background: Precision oncology programs using next-generation sequencing to detect predictive biomarkers are extending therapeutic options for patients with metastatic breast cancer (mBC). Regularly, based on the recommendations of the interdisciplinary molecular tumor board (iMTB), an inclusion in a clinical trial is not possible. In this case, the German health insurance system allows for the application of reimbursement for an off-label drug use. Here, we describe the current challenges and our experience with reimbursement of molecular therapies in mBC. Methods: A total of 100 applications for reimbursement of off-label therapies recommended by an iMTB were filed for patients with mBC, of which 89 were evaluable for this analysis. The approval rate was correlated with the molecular level of evidence of the respective therapy according to the National Center for Tumor Diseases (NCT) and European Society for Medical Oncology Scale for Clinical Actionability of molecular Targets (ESCAT) classification as well as with pretreatment therapy lines. Findings: Overall, 53.9% (48/89) of reimbursement applications were approved. Applications for therapies based on level of evidence m1 (NCT classification), tier I and II (ESCAT classification) had a significantly and clinically relevant increased chance of reimbursement, while a greater number of previous treatment lines had no significantly increased chance of approval, though a trend of approval toward higher treatment lines was detectable. Interpretation: Currently, the German jurisdiction seems to aggravate the clinical implementation of clinically urgently needed molecular therapies.

Journal Section:
Research Article
Keywords:
Metastatic breast cancer, Genomics-guided therapies, Reimbursement, Precision oncology, Translational oncology
1.
Horak P, Heining C, Kreutzfeldt S, Hutter B, Mock A, Hullein J, et al. Comprehensive genomic and transcriptomic analysis for guiding therapeutic decisions in patients with rare cancers. Cancer Discov. 2021;11(11):2780–95.
https://doi.org/10.1158/2159-8290.CD-21-0126
2.
Hlevnjak M, Schulze M, Elgaafary S, Fremd C, Michel L, Beck K, et al. CATCH: a prospective precision oncology trial in metastatic breast cancer. JCO Precis Oncol. 2021;5:676–86.
https://doi.org/10.1200/PO.20.00248
3.
Stenzinger A, Edsjo A, Ploeger C, Friedman M, Frohling S, Wirta V, et al. Trailblazing precision medicine in europe: a joint view by genomic medicine Sweden and the Centers for personalized medicine, ZPM, in Germany. Semin Cancer Biol. 2022;84:242–54.
https://doi.org/10.1016/j.semcancer.2021.05.026
4.
Leichsenring J, Horak P, Kreutzfeldt S, Heining C, Christopoulos P, Volckmar AL, et al. Variant classification in precision oncology. Int J Cancer. 2019;145(11):2996–3010.
https://doi.org/10.1002/ijc.32358
5.
Mateo J, Chakravarty D, Dienstmann R, Jezdic S, Gonzalez-Perez A, Lopez-Bigas N, et al. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Ann Oncol. 2018;29(9):1895–902.
https://doi.org/10.1093/annonc/mdy263
6.
Veenstra DL, Mandelblatt J, Neumann P, Basu A, Peterson JF, Ramsey SD. Health economics tools and precision medicine: opportunities and challenges. Forum Health Econ Policy. 2020;23(1).
https://doi.org/10.1515/fhep-2019-0013
7.
Flaherty KT, Gray R, Chen A, Li S, Patton D, Hamilton SR, et al. The molecular analysis for therapy choice (NCI-MATCH) trial: lessons for genomic trial design. J Natl Cancer Inst. 2020;112(10):1021–9.
https://doi.org/10.1093/jnci/djz245
8.
Mangat PK, Halabi S, Bruinooge SS, Garrett-Mayer E, Alva A, Janeway KA, et al. Rationale and design of the targeted agent and profiling utilization registry study. JCO Precis Oncol. 2018;2018(2):1–14.
https://doi.org/10.1200/PO.18.00122
9.
Massard C, Michiels S, Ferte C, Le Deley MC, Lacroix L, Hollebecque A, et al. High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the MOSCATO 01 trial. Cancer Discov. 2017;7(6):586–95.
https://doi.org/10.1158/2159-8290.CD-16-1396
10.
Worst BC, van Tilburg CM, Balasubramanian GP, Fiesel P, Witt R, Freitag A, et al. Next-generation personalised medicine for high-risk paediatric cancer patients: the INFORM pilot study. Eur J Cancer. 2016;65:91–101.
https://doi.org/10.1016/j.ejca.2016.06.009
11.
Horak P, Klink B, Heining C, Groschel S, Hutter B, Frohlich M, et al. Precision oncology based on omics data: the NCT Heidelberg experience. Int J Cancer. 2017;141(5):877–86.
https://doi.org/10.1002/ijc.30828
12.
Andre F, Bachelot T, Commo F, Campone M, Arnedos M, Dieras V, et al. Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER). Lancet Oncol. 2014;15(3):267–74.
https://doi.org/10.1016/S1470-2045(13)70611-9
13.
Zardavas D, Maetens M, Irrthum A, Goulioti T, Engelen K, Fumagalli D, et al. The AURORA initiative for metastatic breast cancer. Br J Cancer. 2014;111(10):1881–7.
https://doi.org/10.1038/bjc.2014.341
14.
Maetens M, Brown D, Irrthum A, Aftimos P, Viale G, Loibl S, et al. The AURORA pilot study for molecular screening of patients with advanced breast cancer-a study of the breast international group. NPJ Breast Cancer. 2017;3:23.
https://doi.org/10.1038/s41523-017-0026-6
15.
Robert NJ, Dieras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol. 2011;29(10):1252–60.
https://doi.org/10.1200/JCO.2010.28.0982
16.
Kaufman PA, Awada A, Twelves C, Yelle L, Perez EA, Velikova G, et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2015;33(6):594–601.
https://doi.org/10.1200/JCO.2013.52.4892
17.
Tegze B, Szallasi Z, Haltrich I, Penzvalto Z, Toth Z, Liko I, et al. Parallel evolution under chemotherapy pressure in 29 breast cancer cell lines results in dissimilar mechanisms of resistance. PLoS One. 2012;7(2):e30804.
https://doi.org/10.1371/journal.pone.0030804
18.
Almendro V, Cheng YK, Randles A, Itzkovitz S, Marusyk A, Ametller E, et al. Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity. Cell Rep. 2014;6(3):514–27.
https://doi.org/10.1016/j.celrep.2013.12.041
19.
Venkatesan S, Swanton C. Tumor evolutionary principles: how intratumor heterogeneity influences cancer treatment and outcome. Am Soc Clin Oncol Educ Book. 2016;35:e141–9.
https://doi.org/10.1200/EDBK_158930
© 2023 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2023
You do not currently have access to this content.